Business Context and Reporting Period
Company: ImmunityBio, Inc. (IBRX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: ImmunityBio is a biotechnology company focused on developing and commercializing next-generation immunotherapies, primarily anchored by its approved product ANKTIVA (nogapendekin alfa inbakicept), an IL-15 receptor superagonist. The company is commercializing ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and has received approvals in multiple jurisdictions including the U.S., UK, and UAE. The company operates as a single segment and relies heavily on the commercialization of ANKTIVA and the development of its pipeline (including NK-cell therapies and vaccines).
Key Financial Metrics
| Metric (in thousands, except per share) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | Balance Sheet (June 30, 2026) |
|---|---|---|---|
| Total Revenue | $51,240 | $95,446 | — |
| Net Loss | $(230,390) | $(863,187) | — |
| Net Loss Per Share (Basic & Diluted) | $(0.22) | $(0.83) | — |
| Cash and Cash Equivalents | — | — | $75,670 |
| Marketable Securities | — | — | $281,701 |
| Total Current Assets | — | — | $438,980 |
| Total Liabilities | — | — | $1,674,265 |
| Stockholders' Deficit | — | — | $(1,045,761) |
| Accumulated Deficit | — | — | $(4,589,806) |
Debt and Liquidity Highlights:
- Related-Party Convertible Note: Principal balance of $480.0 million; Fair value of $774.35 million (Level 3).
- Revenue Interest Liability (RIPA): $415.09 million.
- Warrant Liabilities: $352.38 million.
- Operating Cash Flow: Net cash used in operating activities was $141.9 million for the six months ended June 30, 2026.
Material Changes vs. Prior Period
Revenue Growth: Total revenue increased 94% year-over-year for the three months ended June 30, 2026, and 122% for the six-month period. This growth is driven by increased sales of ANKTIVA in the U.S. and international markets.
Net Loss Expansion: Net loss increased significantly to $230.4 million (Q2) and $863.2 million (YTD) compared to $92.6 million and $222.2 million in the prior year periods, respectively. The increase is primarily attributable to non-cash fair value adjustments rather than operational expenses.
Key Drivers of Loss:
- Change in Fair Value of Related-Party Convertible Note: A loss of $96.0 million (Q2) and $332.6 million (YTD) due to the revaluation of the note based on the company's stock price.
- Change in Fair Value of Warrant Liabilities: A loss of $44.2 million (Q2) and $339.6 million (YTD) driven by increases in the fair value of warrants.
- Operating Expenses: Research and Development (R&D) expenses increased 10% (Q2) and 24% (YTD) due to higher clinical trial and personnel costs. Selling, General, and Administrative (SG&A) expenses increased 22% (Q2) and 30% (YTD) due to commercialization efforts.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance: The company does not provide specific financial guidance. Management expects operating expenses to increase significantly as they pursue label expansions for ANKTIVA, advance the product pipeline, and execute planned clinical trials. They anticipate needing substantial additional funding to support operations and commercialization.
Going Concern: The filing states that substantial doubt exists regarding the company's ability to continue as a going concern without additional funding or financial support. However, management believes existing cash, marketable securities, product sales, and potential equity offerings or loans from affiliated entities (specifically the Founder/Executive Chairman) will be sufficient to fund operations for at least the next 12 months.
Unusual Items and Contingencies:
- Legal Proceedings:
- Securities Class Action: A complaint filed in March 2026 alleging violations of the Exchange Act regarding an FDA warning letter related to a TV ad and podcast. Lead plaintiff appointed July 2026.
- Shareholder Derivative Actions: Two complaints filed in April 2026 alleging breach of fiduciary duties related to the same FDA warning letter. Consolidated and stayed pending the securities lawsuit.
- SRS/Altor CVR Arbitration: Shareholder Representative Services (SRS) filed a demand for arbitration seeking approximately $164.2 million plus interest, alleging failure to use commercially reasonable efforts to secure FDA approval by the 2022 deadline. Hearing scheduled for January 2027.
- Beike Arbitration: An arbitration regarding a China license agreement concluded in July 2026 with an award denying all claims and counterclaims.
- Regulatory: FDA accepted the sBLA for ANKTIVA for papillary NMIBC without CIS in May 2026, with a PDUFA date of January 6, 2027. The company received an FDA OPDP warning letter in March 2026 regarding promotional communications.
- Contractual Obligations: Significant contingent value rights (CVRs) totaling approximately $304 million are outstanding from the Altor acquisition, payable if ANKTIVA sales exceed $1.0 billion prior to December 31, 2026.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $357.4 million in cash and marketable securities against the $1.67 billion in total liabilities and the $141.9 million operating cash burn rate.
- Debt Valuation Volatility: Assess the impact of the $774 million fair value of the related-party convertible note and $352 million warrant liabilities on reported losses, noting these are non-cash items driven by stock price fluctuations.
- Legal Exposure: Monitor the status of the SRS/Altor CVR arbitration ($164M+ claim) and the securities class action/derivative suits regarding the FDA warning letter.
- Revenue Sustainability: Evaluate the concentration of revenue (top four customers accounted for ~90% of gross revenue in Q2) and the impact of BCG supply shortages on ANKTIVA sales.
- Related-Party Transactions: Review the terms of the RIPA (Revenue Interest Purchase Agreement) and the $480 million convertible note held by an affiliate of the Founder, including conversion rights and subordination.
- Regulatory Milestones: Track the progress of the sBLA for papillary NMIBC (PDUFA Jan 2027) and the potential for additional approvals in NSCLC and other indications.